skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

12 Total results for product and free and sample content found

In Vivo

Curing What Hinders Alzheimer’s Drug Development

By Rachel Laing, Alessia Deglincerti, Mark Ratner 27 Nov 2020

Curing What Hinders Alzheimer’s Drug Development

Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

Topic Alzheimer's Disease Drug Development Landscape

Scrip

AbbVie Calico Extend Their Collaboration On Aging

By Joseph Haas 27 Nov 2020

AbbVie Calico Extend Their Collaboration On Aging

The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.

Topic Alzheimer's Disease

Scrip

Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical

By Mandy Jackson 22 Aug 2018

Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical

Further new data for the Biogen and Eisai drug BAN2401 appear to show it significantly reduces amyloid plaque and cognitive declines in Alzheimer's patients in a dose-dependent manner, but a lot of questions – and skepticism about the data – remain.

Topic Alzheimer's Disease Clinical Trials Research & Development

Pink Sheet

Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance

By Brenda Sandburg 15 May 2018

Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance

US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.

Topic Alzheimer's Disease

Sitetrove

Sitetrove Infographic Roundup - Issue 4 - November - 2017

07 Jan 2018

Sitetrove Infographic Roundup - Issue 4 - November - 2017

November is National Alzheimer’s Disease (AD) Awareness Month. Sitetrove wants to raise awareness by going purple! This infographic offers an overview of the current global investigator landscape and how AD trial experience has shifted over the last 10 years

Topic Alzheimer's Disease

Biomedtracker

BMT Q4 Outlook Report

26 Oct 2017

BMT Q4 Outlook Report

In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Topic Alzheimer's Disease Cancer Approvals

Biomedtracker

Report Extract: Q3 2017 Outlook Report

16 Jul 2017

Report Extract: Q3 2017 Outlook Report

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Topic Alzheimer's Disease Cancer Approvals

Datamonitor Healthcare

EPOCH failure reveals more about clinical trial design

16 Feb 2017

In February 2017, Merck & Co announced the discontinuation of verubecestat’s Phase II/III study, EPOCH, in mild to moderate Alzheimer’s disease due to the high likelihood of missing the primary endpoint.

Topic Alzheimer's Disease

Datamonitor Healthcare

Idalopirdine’s lack of efficacy in Alzheimer’s Phase III trials

13 Feb 2017

Datamonitor healthcare looks at Idalopirdine’s lack of efficacy in Alzheimer’s Phase III trials ends regulatory submission, casting doubt over the 5-HT6 class

Topic Alzheimer's Disease

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: